demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
heparin at therapeutic dose ATTACC ... ACTIV-4a ... REMAP-CAP Anticoagulation

0 studies excluded by filtering options 1